Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Withdrawn 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Endocrine 1

Conditions

Hemorrhage 13Neoplasms 7Leiomyoma 7Breast Neoplasms 6Postoperative Hemorrhage 4Hematologic Neoplasms 4Thrombocytopenia 3Myofibroma 3Meningioma 3Blood Loss, Surgical 3Urinary Bladder Neoplasms 2Stomach Neoplasms 2Seroma 2Seizures 2Prostatic Neoplasms 2Postoperative Complications 2Ovarian Neoplasms 2Menorrhagia 2Head and Neck Neoplasms 2Colonic Neoplasms 2Brain Neoplasms 2Bone Neoplasms 2Wrist Fractures 1Urologic Diseases 1Urinary Tract Infections 1Urinary Retention 1Thromboembolism 1Staphylococcal Infections 1Spasm 1Sleep Initiation and Maintenance Disorders 1

Interventions

pasireotide 7Cabergoline 7Surgical Procedures, Operative 4Temozolomide 3Propofol 3Hydrocortisone 3Dexmedetomidine 3lanreotide 2Sevoflurane 2Saline Solution 2Rosiglitazone 2Radiotherapy 2Radiosurgery 2Proton Therapy 2Octreotide 2Human Growth Hormone 2Dexamethasone 2Desflurane 2Aminolevulinic Acid 2pegvisomant 1parecoxib 1lutetium Lu 177 dotatate 1loxoprofen 1farletuzumab 1entinostat 1corticorelin ovine 1antineoplaston AS 2-1 1antineoplaston A10 1Yoga 1Visual Field Tests 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Pituitary Neoplasms × Tranexamic Acid × Clear all
NCT04863339 2022-04-05

Tranexamic Acid for Blood Loss Minimization in Endoscopic Pituitary Surgery

University of North Carolina, Chapel Hill

Phase 2 Withdrawn
Endocrine

Hemorrhage, Pituitary Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡